HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Faldaprevir for the treatment of hepatitis C.

Abstract
The current treatments for chronic hepatitis C virus (HCV) genotype 1 infection are combinations of direct-acting antivirals, and faldaprevir is one of the new generation of HCV NS3/4A protease inhibitors. At the end of 2013, the US Food and Drug Administration (FDA) approved the HCV NS3/4A protease inhibitor simeprevir and the HCV NS5B polymerase inhibitor sofosbuvir. Simeprevir or sofosbuvir in combination with pegylated interferon and ribavirin are available for clinical use. Faldaprevir, another HCV NS3/4A protease inhibitor that also has fewer adverse events than telaprevir or boceprevir, is under development. Of interest, faldaprevir in combination with pegylated interferon and ribavirin, and interferon-free treatment with faldaprevir in combination with deleobuvir plus ribavirin provides high sustained virological response rates for HCV genotype 1 infection. The aim of this article is to review these data concerning faldaprevir. Faldaprevir in combination with pegylated interferon and ribavirin treatment appears to be associated with fewer adverse events than telaprevir or boceprevir in combination with pegylated interferon and ribavirin, and may be one of the therapeutic options for treatment-naive patients with HCV genotype 1. The interferon-free combination of faldaprevir and deleobuvir with ribavirin was effective for HCV genotype 1 infection and may hold promise for interferon-ineligible and interferon-intolerant patients.
AuthorsTatsuo Kanda, Osamu Yokosuka, Masao Omata
JournalInternational journal of molecular sciences (Int J Mol Sci) Vol. 16 Issue 3 Pg. 4985-96 (Mar 04 2015) ISSN: 1422-0067 [Electronic] Switzerland
PMID25749475 (Publication Type: Journal Article, Review)
Chemical References
  • Aminoisobutyric Acids
  • Antiviral Agents
  • Interferon-alpha
  • NS3 protein, hepatitis C virus
  • NS4 protein, hepatitis C virus
  • Oligopeptides
  • PEG-IFN-SA
  • Quinolines
  • Thiazoles
  • Viral Nonstructural Proteins
  • Polyethylene Glycols
  • faldaprevir
  • Proline
  • Leucine
Topics
  • Aminoisobutyric Acids
  • Antiviral Agents (chemistry, therapeutic use)
  • Drug Therapy, Combination
  • Hepacivirus (genetics)
  • Hepatitis C (drug therapy, genetics, pathology)
  • Humans
  • Interferon-alpha (chemistry, therapeutic use)
  • Leucine (analogs & derivatives)
  • Oligopeptides (chemistry, therapeutic use)
  • Polyethylene Glycols (chemistry, therapeutic use)
  • Proline (analogs & derivatives)
  • Quinolines
  • Thiazoles (chemistry, therapeutic use)
  • Viral Nonstructural Proteins (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: